Nichole Tucker, MA, is the Senior Editor for Targeted Oncology and host of the Targeted Talks podcast. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.
FDA's ODAC Supports Proposed Trials for Dostarlimab in dMMR/MSI-H Locally-Advanced Rectal CancersFebruary 9th 2023
In an 8 to 5 vote, the FDA's Oncologic Drugs Advisory Committee supported the proposed clinical trial for dostarlimab as treatment of locally advanced, treatment-naïve mismatch-repair deficient or microsatellite-instability-high rectal cancer.
Claudin 18.2 Represents New Druggable Target for CLDN18.2+/HER2-, Advanced/Metastatic Gastric and GEJ AdenocarcinomaFebruary 8th 2023
In an interview with Targeted Oncology, Samuel Klempner, MD, discussed the significance of the phase 3 SPOTLIGHT study and the future impact of claudin 18.2 as a biomarker to treat cancers of the stomach and esophagus.
Precision Oncology Inches into Head and Neck Cancer ParadigmFebruary 4th 2023
In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development.
Engaging Oncology Peers in Discussions Around Precision MedicineFebruary 3rd 2023
In an interview with Targeted Oncology™, Manmeet Ahluwalia, MD, discussed the importance of the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium, what to expect from his presentation on brain metastases, and what to expect from presentations by other experts.
Taking on the Challenge to Develop New Therapies for Pediatric Solid TumorsJanuary 31st 2023
Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.
Futibatinib Sustains Benefit in Advanced/Metastatic FGFR2+ iCCAJanuary 25th 2023
Phase 2 FOENIX-CCA2 study results further confirm the safety and efficacy of futibatinib for the treatment of previously treated patients with advanced/metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements.
Adjuvant Atezolizumab Plus Bevacizumab Improve RFS in Early-Stage Hepatocellular CarcinomaJanuary 19th 2023
In IMbrave050, the risk of disease recurrence or death was decreased with adjuvant atezolizumab and bevacizumab compared with active surveillance in patients with early-stage hepatocellular carcinoma.
Perez on Real-World Pola-BR Treatment Outcomes in Patients with R/R LBCLJanuary 16th 2023
In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.
Preventing and Managing Cytomegalovirus After Hematopoietic Stem Cell TransplantJanuary 14th 2023
In an interview with Targeted Oncology, Guenther Koehne, MD, PhD provided a detailed explanation on the impact of cytomegalovirus reactivation post-transplant, cytomegalovirus reactivation prevention, and refractory cytomegalovirus reactivation.
Opioid Distribution for Terminal Cancer Patients Not Equal for Certain Races and EthnicitiesJanuary 12th 2023
Patients with cancer at the end of their life may receive different pain management based on their race/ethnicity. A study has revealed fewer prescriptions and lower doses for 2 racial/ethnic groups.